Morgan Stanley’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-400
| Closed | – | – | 6926 |
|
|
2017
Q4 | $0 | Sell |
400
-1,972
| -83% | -$995 | ﹤0.01% | 6921 |
|
|
2017
Q3 | $1K | Sell |
2,372
-1,420
| -37% | -$498 | ﹤0.01% | 6509 |
|
|
2017
Q2 | $1K | Sell |
3,792
-15,074
| -80% | -$10.9K | ﹤0.01% | 6568 |
|
|
2017
Q1 | $23K | Buy |
18,866
+3,991
| +27% | +$4.99K | ﹤0.01% | 6055 |
|
|
2016
Q4 | $19K | Buy |
14,875
+3,954
| +36% | +$6.88K | ﹤0.01% | 6027 |
|
|
2016
Q3 | $23K | Sell |
10,921
-6,341
| -37% | -$12.5K | ﹤0.01% | 5884 |
|
|
2016
Q2 | $28K | Sell |
17,262
-3,984
| -19% | -$7.64K | ﹤0.01% | 5740 |
|
|
2016
Q1 | $21K | Sell |
21,246
-8,081
| -28% | -$7.88K | ﹤0.01% | 5914 |
|
|
2015
Q4 | $35K | Sell |
29,327
-695,634
| -96% | -$2.23M | ﹤0.01% | 5854 |
|
|
2015
Q3 | $5.39M | Buy |
724,961
+360,724
| +99% | +$2.76M | ﹤0.01% | 2590 |
|
|
2015
Q2 | $2.6M | Buy |
364,237
+147,476
| +68% | +$1.15M | ﹤0.01% | 3382 |
|
|
2015
Q1 | $1.86M | Buy |
216,761
+28,421
| +15% | +$254K | ﹤0.01% | 3641 |
|
|
2014
Q4 | $1.88M | Sell |
188,340
-142,044
| -43% | -$1.21M | ﹤0.01% | 3623 |
|
|
2014
Q3 | $3.27M | Buy |
330,384
+200,546
| +154% | +$2.97M | ﹤0.01% | 3027 |
|
|
2014
Q2 | $2.25M | Buy |
129,838
+106,243
| +450% | +$1.73M | ﹤0.01% | 3397 |
|
|
2014
Q1 | $418K | Sell |
23,595
-3,568
| -13% | -$69K | ﹤0.01% | 4680 |
|
|
2013
Q4 | $497K | Buy |
27,163
+15,496
| +133% | +$293K | ﹤0.01% | 4448 |
|
|
2013
Q3 | $312K | Sell |
11,667
-8,717
| -43% | -$187K | ﹤0.01% | 4638 |
|
|
2013
Q2 | $376K | Buy |
+20,384
| New | +$360K | ﹤0.01% | 4463 |
|
Morgan Stanley's RPRX Position: Q1 2018 in Review
Morgan Stanley sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 400 shares.
Morgan Stanley first reported a position in RPRX in Q2 2013 and held it in 19 quarters. The position peaked at $5.39M in Q3 2015. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Morgan Stanley reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Morgan Stanley sold 400 Repros Therapeutics Inc. shares in Q1 2018.
- Morgan Stanley first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 19 quarters.
- Morgan Stanley's Repros Therapeutics Inc. position peaked at $5.39M in Q3 2015.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Morgan Stanley's 13F filing for Q1 2018, filed 14 May 2018.